The author compares 4DX and EBR, arguing 4DX is overvalued for its market size while EBR has a larger market and 2026 commercial rollout, offering more value under one dollar.
4DX.AX — AVOID Author believes 4DX is overvalued relative to the market size for its CTVQ technology and revenue pipeline despite FDA approval and adoption. The argument is that current price does not justify the addressable market and future revenue.
I think 4dx is over valued for the market size for ctvq technology and the revenue pipeline.
EBR.AX — LONG Author argues EBR with its approved WiSE technology has a much larger market than 4DX and is entering full commercial rollout in 2026, while priced under one dollar, offering more value. The catalyst is the 2026 commercial rollout expanding adoption.
On the other hand EBR with its approved WiSE technology has a much bigger market to cater to and 2026 will be its full commercial roll out. Currently priced under a dollar.